Product Details
Product Details
Product Specification
| Antibody Type | ADC |
| Concentration | 1 mg/ml |
| Endotoxin | <1EU/mg |
| Physical Appearance | Liquid |
| Storage Buffer | Reconstitute the Trastuzumab deruxtecan using 0.9% Sodium Chloride Injection |
| Stability & Storage |
2 to 8 °C for 2 weeks under sterile conditions; -20 °C for 3 months under sterile conditions; -80 °C for 24 months under sterile conditions.
Please avoid repeated freeze-thaw cycles.
|
Background
Trastuzumab deruxtecan (DS-8201a) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
